Genesis MedTech Receives Chinese Market Approval for Antibacterial Absorbable Sutures
Singapore-based medical device company Genesis MedTech has announced that it has received market approval in...
Grand Pharmaceutical’s GSP301 NS Meets Primary Endpoint in Phase III SAR Study
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that its Phase III study (GSP...
Canton Biologics Secures Over RMB 300 Million in Series C Financing for Expansion
Canton Biologics Co., Ltd, a Guangzhou-based Contract Development and Manufacturing Organization (CDMO) specializing in biologic...
Menarini Group Secures Exclusive License for Astellas’ Smyraf in Taiwan
A. Menarini Asia-Pacific Holdings Pte. Ltd, a subsidiary of the Italy-based Menarini Group, has entered...
Haisco Pharmaceutical’s HSK16149 for Post-Herpes Neuralgia Accepted for NMPA Review
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that the National Medical Products...
Asieris Pharmaceuticals’ APL-1202 Shows Positive Interim Analysis in MIBC Trial with BeiGene’s Tislelizumab
China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has revealed positive results from a Phase...
AstraZeneca’s Fasenra Shows Non-Inferior Efficacy to Nucala in EGPA: Phase III Results
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has unveiled the results of a Phase III...
InnoCare Pharma and ArriVent Biopharma Partner on Clinical Study for Advanced NSCLC Treatment
China-based InnoCare Pharma (HKG: 9969; SHA: 688428) has announced that it has received the green...
EMA Approves Astellas’ Xtandi for Non-Metastatic Hormone-Sensitive Prostate Cancer
The European Medicines Agency (EMA) has granted Japan-based Astellas (TYO: 4503) an indication extension approval...
FDA Accepts Takeda’s Filing for Subcutaneous Entyvio as Maintenance Therapy for Crohn’s Disease
The US Food and Drug Administration (FDA) has accepted a filing from Japan-based Takeda (TYO:...
AbbVie’s Skyrizi Outperforms Janssen’s Stelara in Phase III Crohn’s Disease Trial
AbbVie (NYSE: ABBV) has announced early data from a Phase III trial that compared the...
Boehringer Ingelheim Gets NMPA Approval for Brigimadlin Safety and Efficacy Study in China
Germany-based Boehringer Ingelheim (BI) has announced that it has received approval from the National Medical...
NHSA Unveils Measures to Enhance Smart Monitoring and Auditing of Basic Medical Insurance Funds
The National Healthcare Security Administration (NHSA) has released a notification detailing planned measures to improve...
MSD’s Sotatercept Demonstrates Positive Interim Results in Phase III PAH Studies
Merck, Sharp & Dohme (MSD; NYSE: MRK) has presented interim data from Phase III and...
Suzhou Porton Biologics Partners with BRL Medicine to Advance Gene and Cell Therapy Pipeline
China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd has entered into a...
AstraZeneca’s Tagrisso Combination Therapy Shows Improved Efficacy in EGFR-mutated NSCLC
UK-headquartered AstraZeneca (AZ; NASDAQ: AZN) has announced interim Phase III data demonstrating that the addition...
Jiangsu Recbio and Yikang Biological Partner to Develop RSV Preventative Vaccine
Jiangsu Recbio Technology Co., Ltd, a China-based biotechnology company, has entered into a product development...
Janssen Reports Positive Results from Phase Ib/II Study of Rybrevant Combo in EGFR-mutated NSCLC
Johnson & Johnson (J&J; NYSE: JNJ) subsidiary Janssen has provided an update on an ongoing...
AstraZeneca’s Enhertu Shows Promising Results in Phase II HER2-mutant NSCLC Trial
AstraZeneca (AZ; NASDAQ: AZN) has released early data from a Phase II trial investigating the...
Innovent Biologics Plans Share Placement to Raise HKD 2.36 Billion for Global Expansion
China-based biotech Innovent Biologics Inc., (HKG: 1801) has issued a notice stating its intention to...